FDA Oral Contraceptives Guidance "Oversimplifies" Risk Information, J&J Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson is concerned that the draft guidance will not "objectively relate the risks" to physicians. The company also recommends including newer references for risk information.
You may also be interested in...
Oral Contraceptive Labeling Likely To Become More Graphic
FDA is nearing completion of guidance on labeling for combined oral contraceptives with an eye toward improving communication with more visual presentations rather than relying on prose.
FDA Oral Contraceptives Labeling Guidance Removes Mention Of Emergency Use
First draft of guidance listed dosing regimens appropriate for emergency use; PhRMA questioned inclusion of the information in earlier comments.
“Whistleblower” Suits Should Be Encouraged By Rx Manufacturers, Sen. Grassley Says
Schering-Plough’s Claritin settlement prompts letter from Grassley to Schering and 18 other manufacturers. Educating employees about the False Claims Act and their right to file suit is a “step in the right direction” to address fraud, he says.